Abstract
Non-small-cell lung cancer (NSCLC) is a very common disease of the elderly. Its incidence is expected to increase in Western countries because of the ageing of the population and the increase of cancer incidence with age. The purpose of this article is to synthesize the published data available to manage elderly patients with NSCLC at various stages: earlystage, locally advanced inoperable and metastatic. We’ll discuss, for each of the stage of the disease, the respective contributions of chemotherapy, targeted therapies and immunotherapy and their use as sole therapy or in combination with local treatments. International recommendations have been published but they are difficult to apply because of the lack of consensual definition of frailties relevant to make treatment decision and to adapt it. We will also discuss data about the usefulness of geriatric assessment.1877-1203/© 2022 SPLF. Published by Elsevier Masson SAS. All rights reserved.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
